TherapeuticsMD Q3 2025 Earnings Report

TherapeuticsMD EPS Results

• Actual EPS: $0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

TherapeuticsMD Revenue Results

• Actual Revenue: $0.78 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

TherapeuticsMD Announcement Details

• Quarter: Q3 2025
• Date: 11/12/2025
• Time: After Market Closes
• Conference Call Date: Thursday, November 6, 2025
• Conference Call Time: 6:00AM ET

TherapeuticsMD (NASDAQ:TXMD) (NASDAQ:TXMD) is a women's healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause. The company also markets BIJUVA, the first combination bio-identical estrogen and progesterone capsule for the treatment of moderate to severe hot flashes. In addition, TherapeuticsMD is advancing a pipeline of novel contraceptive technologies, including transdermal delivery systems and oral formulations aimed at providing more flexible dosing options.

Founded in 2015 and headquartered in Boca Raton, Florida, TherapeuticsMD has built a leadership team with extensive experience in women’s health and specialty pharmaceuticals. The organization emphasizes strategic partnerships and targeted clinical development to support product launches and lifecycle management. With a commitment to research and patient-centric care, TherapeuticsMD continues to expand its portfolio and strengthen its position in the women’s health market.